Literature DB >> 7745467

Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.

S Mohanam1, R E Sawaya, M Yamamoto, J M Bruner, G L Nicholson, J S Rao.   

Abstract

The cellular receptor for urokinase-type plasminogen activator (uPAR) in glioblastoma cell lines has been identified and found to be similar to the uPAR expressed by other tumor cell lines. Increased levels of uPAR have been found in primary malignant brain tumor tissues, especially highly malignant glioblastoma, and, to a lesser degree, in malignant astrocytomas, suggesting that this receptor might be involved in efficient activation of pro-uPA and confinement of uPA activity on the cell surface of invading brain tumors. The cell surface uPARs in gliomas could constitute an optimum environment for the generation and activity of plasmin, which is known to play a crucial role in the dissolution of the extracellular matrix during tumor cell invasion. In situ hybridization studies have shown that uPAR mRNA is expressed abundantly in tumor cells and is consistently present at the invasive edges of malignant gliomas. These results imply that uPAR is involved in plasmin-catalyzed proteolysis during glioma invasion and that interference with the uPA:uPAR interactions could constitute a novel approach for developing therapeutic strategies to counteract invasion of brain tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7745467     DOI: 10.1007/BF01052890

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

Review 1.  The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.

Authors:  V Ellis; C Pyke; J Eriksen; H Solberg; K Danø
Journal:  Ann N Y Acad Sci       Date:  1992-12-04       Impact factor: 5.691

2.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.

Authors:  D Olson; J Pöllänen; G Høyer-Hansen; E Rønne; K Sakaguchi; T C Wun; E Appella; K Danø; F Blasi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

3.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

Authors:  W Hollas; F Blasi; D Boyd
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

Review 4.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.

Authors:  R Huber; R W Carrell
Journal:  Biochemistry       Date:  1989-11-14       Impact factor: 3.162

Review 5.  Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.

Authors:  P A Andreasen; L Sottrup-Jensen; L Kjøller; A Nykjaer; S K Moestrup; C M Petersen; J Gliemann
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

6.  Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.

Authors:  B S Schwartz
Journal:  J Biol Chem       Date:  1994-03-18       Impact factor: 5.157

7.  Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.

Authors:  J L Gross; D L Behrens; D E Mullins; P L Kornblith; D L Dexter
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

8.  Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.

Authors:  P H Quax; G N van Muijen; E J Weening-Verhoeff; L R Lund; K Danø; D J Ruiter; J H Verheijen
Journal:  J Cell Biol       Date:  1991-10       Impact factor: 10.539

9.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Authors:  R W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; N Behrendt; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  14 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

Review 2.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 3.  Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

Review 4.  Cell migration in the normal and pathological postnatal mammalian brain.

Authors:  Myriam Cayre; Peter Canoll; James E Goldman
Journal:  Prog Neurobiol       Date:  2009-02-11       Impact factor: 11.685

5.  The role of myosin II in glioma invasion of the brain.

Authors:  Christopher Beadle; Marcela C Assanah; Pascale Monzo; Richard Vallee; Steven S Rosenfeld; Peter Canoll
Journal:  Mol Biol Cell       Date:  2008-05-21       Impact factor: 4.138

Review 6.  Diphtheria toxin-based targeted toxin therapy for brain tumors.

Authors:  Yan Michael Li; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

7.  Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

Review 8.  Recent developments on immunotherapy for brain cancer.

Authors:  Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

Review 9.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075

10.  Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.

Authors:  D Albo; V L Rothman; D D Roberts; G P Tuszynski
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.